Sean Reilly, DAIC Publisher

Sean Reilly is healthcare brands group publisher (Imaging Technology News and Diagnostic and Interventional Cardiology) at Scranton Gillette Communications.
 

Blog | Sean Reilly, DAIC Publisher | January 09, 2013

Innovation Exasperation

In a recent LinkedIn Medical Device Group posting, it was noted that DuVal & Associates, P.A. filed a Citizen Petition and Petition for Stay of Action with the FDA, on behalf of the Minnesota Medical Device Alliance (MMDA). See: http://medgroup.biz/FDA-petition

The petition challenges the FDA's practices and interpretations for reviewing 510(k)s and asks the Commissioner to stay the implementation of “Draft Guidance: Evaluating Substantial Equivalence in Premarket Notifications [510(k)],” dated December 27, 2011. It seeks reversion to older guidance until FDA addresses:

Its practice of “stage-gating” reviews (because it leads to an inevitable FDA request to pursue the de novo path); Its interpretation of “general versus specific intended use,” now applied so narrowly that FDA considers almost every new indication for a 510(k) device to be a new intended use; Its interpretation of clinical utility/benefit as part of the substantial equivalence (SE) criteria (because it essentially allows FDA to determine which devices practitioners should use); Its inappropriate use of statutes and regulatory matters extraneous to the SE decision (e.g., cGMP/Quality Systems, MDR, FD&C Act advertising and promotion, and OSHA regulations or CDC guidance); Its application of risk mitigation and “assurance case” principles to 510(k) clearance criteria; Its interpretation when a device has a new technological characteristic which raises new questions of safety and effectiveness; Its failure in stage-gated reviews to review performance data to determine same intended use / technological characteristics and if new safety and effectiveness questions need to be asked; Its practice of dictating the non-clinical and clinical performance data an applicant must generate (instead of reviewing submitted data at face value for an SE decision); and, Its approach to “whistleblowing,” which can lead to risk-averseness for political, not safety, reasons.

 

The petition seems on the mark. Medical device companies are under enormous financial pressures with difficult economies both domestically and abroad. Add to this the 2.3% medical device tax on gross revenues and a highly bureaucratic, overbearing (if you agree with this petition) FDA and you can’t help but envision difficult times ahead for our industry. Innovative small and midsize companies are struggling, and the government and the FDA aren’t helping matters by treating innovation as the problem. Many on the device side seem unable or unwilling to challenge the FDA bureaucracy.  Win the battle but lose the war, perhaps? As one CEO recently shared, "Challenging [the FDA] might make me feel better but it won't resolve the problem." A real shame as, according to this petition, the FDA and some of its policies need to be challenged.

I agree with this petition that the United States may fall behind other countries in having access to state-of-the-art medical devices while they still are state-of-the-art. That ship may have already sailed, in fact. I also agree that innovation – something we have always embraced and encouraged as a great nation – is being thwarted rather than supported. Healthcare consumers and innovative device companies are suffering and will continue to do so if changes aren’t made. 

Despite said doom and gloom, some innovative, well-managed companies will blast through the aforementioned roadblocks and become stronger, particularly as competition drops off. But I’m concerned that it's going to be mostly the largest companies that survive, and innovation might not always be their strongest suit. I’m also concerned that, as competition disappears, medical device prices will increase – not good for consumers or our Healthcare System.

There is a symbiotic relationship between healthcare providers, healthcare consumers, device manufacturers, our government and the FDA. Sadly, the later have too much power and our system, as this petition suggests, is out of balance and in need of correction. If you agree, beat the drums!

Related Content

ICD-10, transition, practices, Richard Milam, EnableSoft, robotic process automation, software testing, education, communication
News | Business| August 13, 2015
Many organizations may be rallying employees and resources in order to make the switch from the ICD-9 to the ICD-10...
ACC, Population Health Retreat, heart disease prevention
News | Information Technology| August 06, 2015
The American College of Cardiology (ACC) convened leaders in all aspects of healthcare the week of July 27 for a two-...
IBM, purchase, Merge Healthcare, $1 billion, Watson
News | Cardiac PACS| August 06, 2015
August 6, 2015 — IBM announced that its Watson Health Cloud will gain the ability to “see” following the planned acqu
Most Wired, CHIME, information technology, secuirty, patient engagement
News | Information Technology| July 10, 2015
Health data security and patient engagement are top priorities for the nation's hospitals, according to results of the...
venture capital funding, VC, healthcare IT, Q2 2015, Mercom Capital Group, IPOs
News | Business| July 09, 2015
Mercom Capital Group llc, a global communications and research firm, released its report on funding and mergers and...
HIMSS, survey, cybersecurity, cyberattacks, healthcare organizations, IT
Feature | Information Technology| June 30, 2015
Cybersecurity was identified as an increased business priority over the past year according to 87 percent of...
CPeH, CMS, ONC, Meaningful Use Stage 3 requirements, comments
News | Information Technology| June 10, 2015
The nation's top consumer, patient and labor advocates recently praised the proposed Stage 3 Meaningful Use rules,...
News | Information Technology| June 05, 2015
At Health Datapalooza, the Acting Centers for Medicare & Medicaid Services (CMS) Administrator Andy Slavitt...
CDS, clinical decision support, Rand Corp., study, appropriateness
Feature | Clinical Decision Support| June 04, 2015
Using tools that help physicians decide whether to use expensive imaging studies can help reduce the ordering of...
HIMSS, CMS, comments, Meaningful Use, Stage 3
News | Information Technology| May 29, 2015
The Healthcare Information and Management Systems Society (HIMSS) submitted comments to the Department of Health and...
Overlay Init